These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30160874)

  • 1. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Presidential Lecture: Panel discussion: Preemptive Medicine from the Perspective of Physicians: Lung Cancer].
    Hagiwara K
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1808-11. PubMed ID: 30160874
    [No Abstract]   [Full Text] [Related]  

  • 2. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Presidential Lecture: Panel discussion: Preemptive Strategies in Internal Medicine: Introduction].
    Yanagita M; Kimura H
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1802. PubMed ID: 30160918
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicine. Why a new cancer drug works well, in some patients.
    Marx J
    Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
    [No Abstract]   [Full Text] [Related]  

  • 5. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Presidential Lecture: Panel discussion: Preemptive Medicine for Diabetes Mellitus].
    Inagaki N; Fujita N; Kimura H; Hamamatsu K; Sano K; Hirai M; Murakami A; Saji H; Fujimoto H
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1803-7. PubMed ID: 30160872
    [No Abstract]   [Full Text] [Related]  

  • 6. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Presidential Lecture: Panel discussion: Preemptive Medicine Based on Fetal Programming].
    Kubota T
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1825-30. PubMed ID: 30160878
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 8. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
    Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
    J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
    [No Abstract]   [Full Text] [Related]  

  • 9. Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
    Yang TY; Tsai CR; Chen KC; Hsu KH; Lee HM; Chang GC
    J Clin Oncol; 2011 Jun; 29(16):e468-9. PubMed ID: 21422421
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status and study activity of lung cancer in Japan.
    Nukiwa T
    Respir Investig; 2014 Nov; 52(6):315-6. PubMed ID: 25453373
    [No Abstract]   [Full Text] [Related]  

  • 11. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.
    Kuo YW; Wu SG; Ho CC; Shih JY
    J Thorac Oncol; 2010 Dec; 5(12):2039-40. PubMed ID: 21102267
    [No Abstract]   [Full Text] [Related]  

  • 12. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
    Couzin J
    Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
    [No Abstract]   [Full Text] [Related]  

  • 14. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
    Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
    J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease and gefitinib.
    Lim KH; Chang YH
    N Engl J Med; 2010 Oct; 363(16):1579; author reply 1579-80. PubMed ID: 20949670
    [No Abstract]   [Full Text] [Related]  

  • 17. A complex deletion/insertion on exon 19 of the EGFR gene predicts response to gefitinib.
    Luque A; Arriola E; Martínez-Avilés L; Vollmer I
    J Thorac Oncol; 2014 Jun; 9(6):e47-8. PubMed ID: 24828672
    [No Abstract]   [Full Text] [Related]  

  • 18. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
    Hata A; Masago K; Katakami N; Imai Y; Yatabe Y
    J Thorac Oncol; 2014 Aug; 9(8):e64-5. PubMed ID: 25157783
    [No Abstract]   [Full Text] [Related]  

  • 19. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 20. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.